EyePoint Pharmaceuticals, Inc. (EYPT) Financial Statements
Industry: Laboratory Analytical Instruments
In fiscal 2025, EyePoint Pharmaceuticals reported revenue of $31.4M, down 27.5% from $43.3M the year before. Net income was -$232.0M (a -739.4% net margin), or -$3.17 per diluted share. Operating margin was -776.0%. Operating activities generated -$240.1M of cash, leaving -$243.4M of free cash flow. At fiscal year end, EyePoint Pharmaceuticals held $364.0M in total assets against $57.9M in total liabilities, including $101.8M of cash and equivalents.
Open the full interactive EyePoint Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
EyePoint Pharmaceuticals Key Stats
| Share Price | $3.07 |
|---|---|
| Market Cap | $265.7M |
| Revenue YoY Growth | -27.5% |
| 52-Week Range | $3.07 – $18.85 |
| Shares Outstanding | 86.5 million (basic, 2026 Q2) |
EyePoint Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $34.4M | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Operating Income | -$37.3M | -$55.3M | -$99.6M | -$75.1M | -$145.9M | -$243.4M |
| Pre-Tax Income | -$45.4M | -$58.4M | -$102.3M | -$70.7M | -$130.8M | -$231.7M |
| Income Tax | $0 | $0 | $0 | $83,000 | $90,000 | $279,000 |
| Net Income | -$45.4M | -$58.4M | -$102.3M | -$70.8M | -$130.9M | -$232.0M |
| Diluted EPS | -$3.54 | -$2.03 | -$2.74 | -$1.82 | -$2.32 | -$3.17 |
EyePoint Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $966,000 | $619,000 | $696,000 | $507,000 |
| Net Income | -$59.7M | -$67.6M | -$84.8M | -$94.5M |
| Diluted EPS | -$0.85 | -$0.92 | -$0.99 | -$1.09 |
EyePoint Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $44.9M | $178.6M | $95.6M | $281.3M | $99.7M | $101.8M |
| Current Assets | $63.1M | $237.7M | $172.8M | $344.8M | $383.3M | $328.7M |
| Total Assets | $91.7M | $263.4M | $180.4M | $355.2M | $418.5M | $364.0M |
| Current Liabilities | $14.9M | $23.7M | $34.5M | $63.3M | $49.0M | $37.0M |
| Total Long-Term Debt | $38.0M | $36.6M | $30.0M | — | — | — |
| Total Liabilities | $73.2M | $79.0M | $84.0M | $88.9M | $82.0M | $57.9M |
| Shareholders' Equity | $18.5M | $184.4M | $96.4M | $266.3M | $336.5M | $306.1M |
EyePoint Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$14.4M | -$50.1M | -$65.0M | $1.9M | -$126.2M | -$240.1M |
| Cash From Investing | -$362,000 | -$33.1M | -$17.3M | -$3.3M | -$219.4M | $68.6M |
| Cash From Financing | $37.5M | $216.9M | -$690,000 | $187.1M | $164.0M | $173.6M |
| Free Cash Flow | -$14.8M | -$50.3M | -$67.2M | -$1.6M | -$130.3M | -$243.4M |
Figures from EyePoint Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full EyePoint Pharmaceuticals financials page for every line item.
EyePoint Pharmaceuticals Company Profile
| Ticker | EYPT |
|---|---|
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Headquarters | Watertown, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001314102 |
Frequently Asked Questions
What was EyePoint Pharmaceuticals' revenue in fiscal 2025?
EyePoint Pharmaceuticals (EYPT) reported revenue of $31.4M for fiscal 2025.
What is EyePoint Pharmaceuticals' annual revenue history?
EyePoint Pharmaceuticals' annual revenue by fiscal year: 2020: $34.4M; 2021: $36.9M; 2022: $41.4M; 2023: $46.0M; 2024: $43.3M; 2025: $31.4M.
What was EyePoint Pharmaceuticals' net income in fiscal 2025?
EyePoint Pharmaceuticals reported net income of -$232.0M for fiscal 2025.
What was EyePoint Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
EyePoint Pharmaceuticals' diluted EPS was -$3.17 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did EyePoint Pharmaceuticals generate in fiscal 2025?
EyePoint Pharmaceuticals generated -$243.4M of free cash flow in fiscal 2025.
What was EyePoint Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), EyePoint Pharmaceuticals reported revenue of $507,000.
How many shares of EyePoint Pharmaceuticals are outstanding?
EyePoint Pharmaceuticals reported a weighted average of 86.5 million basic shares outstanding in 2026 Q2.
What is EyePoint Pharmaceuticals' market cap?
Based on its latest closing price, EyePoint Pharmaceuticals (EYPT) has a market capitalization of about $265.7M.
When does EyePoint Pharmaceuticals' fiscal year end?
EyePoint Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is EyePoint Pharmaceuticals headquartered?
EyePoint Pharmaceuticals lists its business address in Watertown, Massachusetts in its SEC filings.